Exploring the sites and kinetics of bronchodilator response to β-2 agonists in asthma
Lucas Demey, Alain Van Muylem, Andreï Malinovschi, Amaryllis Haccuria, Silvia Pérez-Bogerd, Alain Michils
Abstract
Lucas Demey, Alain Van Muylem, Andreï Malinovschi, Amaryllis Haccuria, Silvia Pérez-Bogerd, Alain Michils
Abstract
FEV1 increase usually observed after tHe inhalation of short-acting β2-agonists in asthma patients tends to involve peripheral airways. This study shows that the heterogeneity of responses to short-acting β2-agonists in asthma not only involves distinct sites of bronchodilation, but also distinct sequences between these sites. This indicates that a detailed understanding of the bronchodilator effect of β2-agonists in asthma should not be limited to studying its early impact on FEV1.
OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
FEV1 increase usually observed after tHe inhalation of short-acting β2-agonists in asthma patients tends to involve peripheral airways. This study shows that the heterogeneity of responses to short-acting β2-agonists in asthma not only involves distinct sites of bronchodilation, but also distinct sequences between these sites. This indicates that a detailed understanding of the bronchodilator effect of β2-agonists in asthma should not be limited to studying its early impact on FEV1.
Key concepts: Bronchodilation, Bronchodilator, Asthma, Exhaled nitric oxide, Salbutamol, Inhalation, Medicine, Bronchodilator Agents